What is Phlo Technologies?
Phlo Technologies is a digital health company focused on revolutionizing medication access. Its core vision is to provide faster, easier, and more convenient access to prescriptions, eliminating the need for patients to queue at physical pharmacies. The company facilitates ordering medication from home and offers contact-free delivery, a critical service in today's healthcare landscape. This approach addresses a significant pain point in traditional pharmaceutical services, aiming to improve patient convenience and adherence.
How much funding has Phlo Technologies raised?
Phlo Technologies has raised a total of $25.6M across 3 funding rounds:
Other Financing Round
$2.1M
Series A
$12.3M
Private Equity
$11.2M
Other Financing Round (2020): $2.2M, investors not publicly disclosed
Series A (2022): $12.3M, investors not publicly disclosed
Private Equity (2024): $11.2M supported by Par Equity
Key Investors in Phlo Technologies
Par Equity
Par Equity is a venture capital firm based in Edinburgh and Leeds, specializing in investing in innovative, high-growth technology companies from Seed to Series A. With a focus on deep tech and enterprise software, the company seeks to partner with exceptional teams to bring disruptive technologies to market.
What's next for Phlo Technologies?
With the recent major strategic investment, Phlo Technologies is poised to accelerate its growth trajectory. The enterprise-level funding suggests a focus on scaling operations, enhancing technological infrastructure, and potentially expanding its service reach. This capital infusion will likely support further development of its logistics network and digital platform, solidifying its position as a key player in the digital health and pharmacy delivery market. The company's strategic direction will likely involve deepening its market penetration and optimizing its delivery capabilities to meet increasing demand for convenient healthcare solutions.
See full Phlo Technologies company page
